Abstract:The study of modified RNA known as epitranscriptomics has become increasingly relevant in our understanding of disease-modifying mechanisms. Methylation of N6 adenosine (m6A) and C5 cytosine (m5C) bases occur on mRNAs, tRNA, mt-tRNA, and rRNA species as well as non-coding RNAs. With emerging knowledge of RNA binding proteins that act as writer, reader, and eraser effector proteins, comes a new understanding of physiological processes controlled by these systems. Such processes when spatiotemporally disrupted within cellular nanodomains in highly specialized tissues such as the brain, give rise to different forms of disease. In this review, we discuss accumulating evidence that changes in the m6A and m5C methylation systems contribute to neurocognitive disorders. Early studies first identified mutations within FMR1 to cause intellectual disability Fragile X syndromes several years before FMR1 was identified as an m6A RNA reader protein. Subsequently, familial mutations within the m6A writer gene METTL5, m5C writer genes NSUN2, NSUN3, NSUN5, and NSUN6, as well as THOC2 and THOC6 that form a protein complex with the m5C reader protein ALYREF, were recognized to cause intellectual development disorders. Similarly, differences in expression of the m5C writer and reader effector proteins, NSUN6, NSUN7, and ALYREF in brain tissue are indicated in individuals with Alzheimer's disease, individuals with a high neuropathological load or have suffered traumatic brain injury. Likewise, an abundance of m6A reader and anti-reader proteins are reported to change across brain regions in Lewy bodies diseases, Alzheimer's disease, and individuals with high cognitive reserve. m6A-modified RNAs are also reported significantly more abundant in dementia with Lewy bodies brain tissue but significantly reduced in Parkinson's disease tissue, whilst modified RNAs are misplaced within diseased cells, particularly where synapses are located. In parahippocampal brain tissue, m6A modification is enriched in transcripts associated with psychiatric disorders including conditions with clear cognitive deficits. These findings indicate a diverse set of molecular mechanisms are influenced by RNA methylation systems that can cause neuronal and synaptic dysfunction underlying neurocognitive disorders. Targeting these RNA modification systems brings new prospects for neural regenerative therapies.

The tRNA regulome in neurodevelopmental and neuropsychiatric disease

tRNA Modifications and Dysregulation: Implications for Brain Diseases

Lost in translation: How neurons cope with tRNA decoding

Cell-type-specific expression of tRNAs in the brain regulates cellular homeostasis

Dysregulation of RNA modification systems in clinical populations with neurocognitive disorders

Epitranscriptomic regulation of transcriptome plasticity in development and diseases of the brain

Methylation modifications in tRNA and associated disorders: Current research and potential therapeutic targets

tRNA modifications inform tissue specific mRNA translation and codon optimization.

Transfer RNA levels are tuned to support differentiation during Drosophila neurogenesis

Trna Modifications and Modifying Enzymes in Disease, the Potential Therapeutic Targets

Post-Transcriptional Trafficking and Regulation of Neuronal Gene Expression

Biogenesis, Function, and Landscape of Tsrnas in Central Nervous System Diseases

tRNA and tsRNA: From Heterogeneity to Multifaceted Regulators

tRNAs as regulators in gene expression

Unraveling the Pathways to Neuronal Homeostasis and Disease: Mechanistic Insights into the Role of RNA-Binding Proteins and Associated Factors

Regulation of mRNA Translation in Neurons-A Matter of Life and Death

tRNA modifications and tRNA-derived small RNAs: new insights of tRNA in human disease

Epigenetic regulation of neurotransmitter signaling in neurological disorders

tsRNA modifications: An emerging layer of biological regulation in disease

Transfer RNA-Derived Small RNAs: Another Layer of Gene Regulation and Novel Targets for Disease Therapeutics

Mutual regulation of noncoding RNAs and RNA modifications in psychopathology: Potential therapeutic targets for psychiatric disorders?